アルコール性肝炎(Alcoholic Hepatitis):治療薬開発パイプライン動向(2015年上半期版)

◆英語タイトル:Alcoholic Hepatitis - Pipeline Review, H1 2015
◆商品コード:GMDHC6449IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2015年3月19日
◆ページ数:56
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界におけるアルコール性肝炎(Alcoholic Hepatitis)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・アルコール性肝炎(Alcoholic Hepatitis)の概要
・アルコール性肝炎(Alcoholic Hepatitis)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・アルコール性肝炎(Alcoholic Hepatitis)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・アルコール性肝炎(Alcoholic Hepatitis)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・アルコール性肝炎(Alcoholic Hepatitis)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Alcoholic Hepatitis – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Alcoholic Hepatitis – Pipeline Review, H1 2015’, provides an overview of the Alcoholic Hepatitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Alcoholic Hepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcoholic Hepatitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Alcoholic Hepatitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Alcoholic Hepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Alcoholic Hepatitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Alcoholic Hepatitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Alcoholic Hepatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Alcoholic Hepatitis Overview 6
Therapeutics Development 7
Pipeline Products for Alcoholic Hepatitis – Overview 7
Pipeline Products for Alcoholic Hepatitis – Comparative Analysis 8
Alcoholic Hepatitis – Therapeutics under Development by Companies 9
Alcoholic Hepatitis – Therapeutics under Investigation by Universities/Institutes 10
Alcoholic Hepatitis – Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Alcoholic Hepatitis – Products under Development by Companies 13
Alcoholic Hepatitis – Products under Investigation by Universities/Institutes 14
Alcoholic Hepatitis – Companies Involved in Therapeutics Development 15
Alfact Innovation 15
Conatus Pharmaceuticals Inc. 16
Generon (Shanghai) Corporation Ltd. 17
Immuron Limited 18
Intercept Pharmaceuticals, Inc. 19
Oncozyme Pharma Inc. 20
Alcoholic Hepatitis – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
ALF-5755 – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
emricasan – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
F-652 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
IMM-124E – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
obeticholic acid – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Oligonucleotide to Inhibit miRNA-155 for Alcoholic Liver Disease – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
pentamidine isethionate – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Alcoholic Hepatitis – Recent Pipeline Updates 44
Alcoholic Hepatitis – Dormant Projects 52
Alcoholic Hepatitis – Product Development Milestones 53
Featured News & Press Releases 53
Sep 11, 2013: Conatus Pharmaceuticals Initiates Phase 2b Trial of Emricasan in Acute-on-Chronic Liver Failure Patients 53
Sep 10, 2013: Conatus Pharmaceuticals’ Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

[List of Tables]
Number of Products under Development for Alcoholic Hepatitis, H1 2015 7
Number of Products under Development for Alcoholic Hepatitis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Alcoholic Hepatitis - Pipeline by Alfact Innovation, H1 2015 15
Alcoholic Hepatitis - Pipeline by Conatus Pharmaceuticals Inc., H1 2015 16
Alcoholic Hepatitis - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2015 17
Alcoholic Hepatitis - Pipeline by Immuron Limited, H1 2015 18
Alcoholic Hepatitis - Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 19
Alcoholic Hepatitis - Pipeline by Oncozyme Pharma Inc., H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 23
Number of Products by Stage and Mechanism of Action, H1 2015 25
Number of Products by Stage and Route of Administration, H1 2015 27
Number of Products by Stage and Molecule Type, H1 2015 29
Alcoholic Hepatitis Therapeutics - Recent Pipeline Updates, H1 2015 44
Alcoholic Hepatitis - Dormant Projects, H1 2015 52

[List of Figures]
Number of Products under Development for Alcoholic Hepatitis, H1 2015 7
Number of Products under Development for Alcoholic Hepatitis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Top 10 Targets, H1 2015 22
Number of Products by Stage and Top 10 Targets, H1 2015 23
Number of Products by Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Top 10 Routes of Administration, H1 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27
Number of Products by Top 10 Molecule Types, H1 2015 28
Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

【掲載企業】

Alfact Innovation
Conatus Pharmaceuticals Inc.
Generon (Shanghai) Corporation Ltd.
Immuron Limited
Intercept Pharmaceuticals, Inc.
Oncozyme Pharma Inc.

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ アルコール性肝炎(Alcoholic Hepatitis):治療薬開発パイプライン動向(2015年上半期版)(Alcoholic Hepatitis - Pipeline Review, H1 2015)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆